Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL

Annals of Hematology

Volumn 91, Issue 7, 2012, Pages 997-1005

  Suzuki, Yuhko ^a   Yoshida, Tsutomu ^a   Wang, Guoqin ^a   Togano, Tomiteru ^a   Miyamoto, Shunsuke ^a   Miyazaki, Koji ^a   Iwabuchi, Keiichi ^a   Nakayama, Meijin ^a   Horie, Ryouichi ^a   Niitsu, Nozomi ^b   Sato, Yuichi ^c   Nakamura, Naoya ^d  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

CD20; DLBCL; Flow cytometry; Prognosis

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84862757976     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1407-4     Document Type: Article

References (35)

1. Stein H, Chan JKC, Warnke RA, Gatter KC, Chan WC, Campo E, Jaffe ES (2008) Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO, Geneva, pp 233-237
2. R Aoki K Karube Y Sugita Y Nomura K Shimizu Y Kimura K Hashikawa N Suefuji M Kikuchi K Ohshima 2008 Distribution of malignant lymphoma in Japan: analysis of 2,260 cases, 2001-2006 Pathol Int 58 3 174 182 10.1111/j.1440-1827. 2007.02207.x 18251781 10.1111/j.1440-1827.2007.02207.x
3. TF Tedder P Engel 1994 CD20: a regulator of cell-cycle progression of B lymphocytes Immunol Today 15 9 450 454 7524522 10.1016/0167-5699(94)90276-3 1:CAS:528:DyaK2cXmtValsL4%3D
4. JA Ernst H Li HS Kim GR Nakamura DG Yansura RL Vandlen 2005 Isolation and characterization of the B-cell marker CD20 Biochemistry 44 46 15150 15158 10.1021/bi0511078 16285718 10.1021/bi0511078 1:CAS:528:DC%2BD2MXhtFertLvM
5. TL O'Keefe GT Williams SL Davies MS Neuberger 1998 Mice carrying a CD20 gene disruption Immunogenetics 48 2 125 132 9634476 10.1007/s002510050412
6. TW Kuijpers RJ Bende PA Baars A Grummels IA Derks KM Dolman T Beaumont TF Tedder CJ van Noesel E Eldering RA van Lier 2010 CD20 deficiency in humans results in impaired T cell-independent antibody responses J Clin Invest 120 1 214 222 10.1172/JCI40231 20038800 10.1172/JCI40231 1:CAS:528: DC%2BC3cXislWmsQ%3D%3D
7. DG Maloney TM Liles DK Czerwinski C Waldichuk J Rosenberg A Grillo-Lopez R Levy 1994 Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 84 8 2457 2466 7522629 1:STN:280:DyaK2M%2Fgt12ltg%3D%3D
8. W Alduaij A Ivanov J Honeychurch EJ Cheadle S Potluri SH Lim K Shimada CH Chan A Tutt SA Beers MJ Glennie MS Cragg TM Illidge 2011 Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies Blood 117 17 4519 4529 10.1182/blood-2010-07-296913 21378274 10.1182/blood-2010-07-296913 1:CAS:528:DC%2BC3MXlvFKlsrg%3D
9. I Avivi S Robinson A Goldstone 2003 Clinical use of rituximab in haematological malignancies Br J Cancer 89 8 1389 1394 10.1038/sj.bjc.6601187 14562003 10.1038/sj.bjc.6601187 1:CAS:528:DC%2BD3sXotFeks7k%3D
10. SA Beers RR French HT Chan SH Lim TC Jarrett RM Vidal SS Wijayaweera SV Dixon H Kim KL Cox JP Kerr DA Johnston PW Johnson JS Verbeek MJ Glennie MS Cragg 2010 Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection Blood 115 25 5191 5201 10.1182/blood-2010- 01-263533 20223920 10.1182/blood-2010-01-263533 1:CAS:528:DC%2BC3cXovVWltLw%3D
11. BD Cheson 2010 Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies J Clin Oncol 28 21 3525 3530 10.1200/JCO.2010.27.9836 20458041 10.1200/JCO.2010.27.9836 1:CAS:528: DC%2BC3cXhtVGisL7K
12. R Seki K Ohshima K Nagafuji T Fujisaki N Uike F Kawano H Gondo S Makino T Eto Y Moriuchi F Taguchi T Kamimura H Tsuda R Ogawa K Shimoda K Yamashita K Suzuki H Suzushima K Tsukazaki M Higuchi A Utsunomiya M Iwahashi Y Imamura K Tamura J Suzumiya M Yoshida Y Abe T Matsumoto T Okamura 2010 Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group Int J Hematol 91 2 258 266 10.1007/s12185-009-0475-2 20066574 10.1007/s12185-009-0475-2 1:CAS:528:DC%2BC3cXivFGqtbg%3D
13. P Feugier A Van Hoof C Sebban P Solal-Celigny R Bouabdallah C Ferme B Christian E Lepage H Tilly F Morschhauser P Gaulard G Salles A Bosly C Gisselbrecht F Reyes B Coiffier 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 18 4117 4126 10.1200/JCO.2005.09.131 15867204 10.1200/JCO.2005.09.131 1:CAS:528: DC%2BD2MXmt1elsr0%3D
14. M Pfreundschuh L Trumper A Osterborg R Pettengell M Trneny K Imrie D Ma D Gill J Walewski PL Zinzani R Stahel S Kvaloy O Shpilberg U Jaeger M Hansen T Lehtinen A Lopez-Guillermo C Corrado A Scheliga N Milpied M Mendila M Rashford E Kuhnt M Loeffler 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 5 379 391 10.1016/S1470-2045(06)70664-7 16648042 10.1016/S1470-2045(06)70664-7 1:CAS:528:DC%2BD28XjvFWlsbw%3D
15. LH Sehn J Donaldson M Chhanabhai C Fitzgerald K Gill R Klasa N MacPherson S O'Reilly JJ Spinelli J Sutherland KS Wilson RD Gascoyne JM Connors 2005 Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 22 5027 5033 10.1200/JCO.2005.09.137 15955905 10.1200/JCO.2005.09.137 1:CAS:528:DC%2BD2MXpsFWmtLs%3D
16. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah P Morel E Van Den Neste G Salles P Gaulard F Reyes P Lederlin C Gisselbrecht 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 4 235 242 10.1056/NEJMoa011795 11807147 10.1056/NEJMoa011795 1:CAS:528:DC%2BD38XmslGgsw%3D%3D
17. B Coiffier 2002 Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma Semin Oncol 29 2 Suppl 6 18 22 12040530 10.1053/sonc.2002.32749 1:CAS:528:DC%2BD38XltVOjur4%3D
18. SH Olejniczak CC Stewart K Donohue MS Czuczman 2006 A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry Immunol Invest 35 1 93 114 10.1080/08820130500496878 16531332 10.1080/08820130500496878 1:CAS:528:DC%2BD28XisVarurw%3D
19. NA Johnson M Boyle A Bashashati S Leach A Brooks-Wilson LH Sehn M Chhanabhai RR Brinkman JM Connors AP Weng RD Gascoyne 2009 Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival Blood 113 16 3773 3780 10.1182/blood-2008-09-177469 19029441 10.1182/blood-2008-09- 177469 1:CAS:528:DC%2BD1MXlt1yjsLc%3D
20. WA Geary HF Frierson DJ Innes DE Normansell 1993 Quantitative criteria for clonality in the diagnosis of B-cell non-Hodgkin's lymphoma by flow cytometry Mod Pathol 6 2 155 161 8483885 1:STN:280:DyaK3s3kvVWmug%3D%3D
21. M Yamaguchi N Nakamura R Suzuki Y Kagami M Okamoto R Ichinohasama T Yoshino J Suzumiya T Murase I Miura K Ohshima M Nishikori J Tamaru M Taniwaki M Hirano Y Morishima R Ueda H Shiku S Nakamura 2008 De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients Haematologica 93 8 1195 1202 10.3324/haematol.12810 18556402 10.3324/haematol.12810
22. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors TA Lister J Vose A Grillo-Lopez A Hagenbeek F Cabanillas D Klippensten W Hiddemann R Castellino NL Harris JO Armitage W Carter R Hoppe GP Canellos 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 4 1244 10561185 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D
23. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymhoid tissues. WHO classification of Tumours of Haematopoietic and Lymhoid Tissues. International Agency for Research on Cancer, Lyon
24. M Shenkin R Babu R Maiese 2007 Accurate assessment of cell count and viability with a flow cytometer Cytometry B Clin Cytom 72 5 427 432 10.1002/cyto.b.20179 17266154
25. DY Mason WM Comans-Bitter JL Cordell MA Verhoeven JJ van Dongen 1990 Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen Am J Pathol 136 6 1215 1222 1694056 1:CAS:528:DyaK3cXltlShtr0%3D
26. HY Dong P Browne Z Liu M Gangi 2008 PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation Histopathology 53 3 278 287 10.1111/j.1365-2559.2008.03091.x 18643853 10.1111/j.1365-2559.2008.03091.x 1:STN:280:DC%2BD1cnmvVKgsw%3D%3D
27. AS Korganow AM Knapp H Nehme-Schuster P Soulas-Sprauel V Poindron JL Pasquali T Martin 2010 Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression J Autoimmun 34 4 426 434 10.1016/j.jaut.2009.11.002 19963348 10.1016/j.jaut.2009.11.002 1:CAS:528:DC%2BC3cXltF2msbg%3D
28. SL Nutt P Urbanek A Rolink M Busslinger 1997 Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus Genes Dev 11 4 476 491 9042861 10.1101/gad.11.4.476 1:CAS:528:DyaK2sXhsFartbw%3D
29. T Katzenberger A Lohr S Schwarz M Dreyling J Schoof C Nickenig S Stilgenbauer J Kalla MM Ott HK Muller-Hermelink G Ott 2003 Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell Blood 101 2 699 702 10.1182/blood-2002-06-1726 12393524 10.1182/blood-2002-06-1726 1:CAS:528:DC%2BD3sXkvVajsA%3D%3D
30. S Molica D Levato A Dattilo A Mannella 1998 Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins Eur J Haematol 60 1 47 52 10.1111/j.1365-2141.2008.07012.x 9451427 10.1111/j.1600-0609.1998.tb00995.x 1:CAS:528:DyaK1cXnvVylsA%3D%3D
31. CS Tam J Otero-Palacios LV Abruzzo JL Jorgensen A Ferrajoli WG Wierda S Lerner S O'Brien MJ Keating 2008 Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients Br J Haematol 141 1 36 40 10.1111/j.1365-2141.2008.07012.x 18324964 10.1111/j.1365-2141.2008.07012.x
32. L Ginaldi M De Martinis E Matutes N Farahat R Morilla D Catovsky 1998 Levels of expression of CD19 and CD20 in chronic B cell leukaemias J Clin Pathol 51 5 364 369 9708202 10.1136/jcp.51.5.364 1:STN:280:DyaK1czntlCqtA%3D%3D
33. LM Morton SS Wang SS Devesa P Hartge DD Weisenburger MS Linet 2006 Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 1 265 276 10.1182/blood-2005-06-2508 16150940 10.1182/blood-2005-06-2508 1:CAS:528:DC%2BD28XhsVGlsg%3D%3D
34. Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H (2008) Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO, Geneva
35. N Niitsu M Okamoto S Aoki H Okumura T Yoshino I Miura M Hirano 2006 Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma Ann Hematol 85 6 374 380 10.1007/s00277-006-0080-x 16518603 10.1007/s00277-006-0080- x 1:CAS:528:DC%2BD28Xjs1KksLw%3D